Repligen (NASDAQ:RGEN) Shares Down 2.2% – Should You Sell?

Repligen Co. (NASDAQ:RGEN) dropped 2.2% during mid-day trading on Wednesday . The company traded as low as $141.13 and last traded at $141.82. Approximately 19,791 shares were traded during trading, a decline of 97% from the average daily volume of 661,426 shares. The stock had previously closed at $144.98.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and reduced their price objective for the stock from $180.00 to $155.00 in a research note on Wednesday, June 26th. UBS Group decreased their price objective on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Royal Bank of Canada reiterated an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. JPMorgan Chase & Co. raised their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Finally, Wells Fargo & Company started coverage on shares of Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Repligen currently has an average rating of “Moderate Buy” and an average target price of $190.25.

Repligen Stock Up 2.9 %

The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The company’s 50 day moving average price is $145.76 and its 200 day moving average price is $148.74. The firm has a market capitalization of $7.96 billion, a price-to-earnings ratio of -3,552.61, a P/E/G ratio of 4.13 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business had revenue of $154.07 million for the quarter, compared to analyst estimates of $154.11 million. During the same period in the prior year, the company earned $0.53 earnings per share. The company’s revenue was down 3.2% on a year-over-year basis. As a group, research analysts forecast that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In related news, VP Ralf Kuriyel sold 4,465 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the transaction, the vice president now owns 19,261 shares of the company’s stock, valued at $3,190,969.87. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Repligen news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Ralf Kuriyel sold 4,465 shares of Repligen stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the transaction, the vice president now directly owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Andra AP fonden purchased a new stake in shares of Repligen during the 2nd quarter worth about $25,000. International Assets Investment Management LLC acquired a new stake in Repligen in the second quarter valued at approximately $33,000. UMB Bank n.a. increased its position in shares of Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 130 shares in the last quarter. Lazard Asset Management LLC raised its stake in shares of Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after buying an additional 136 shares during the period. Finally, Blue Trust Inc. raised its stake in shares of Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.